These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 2664296

  • 1. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
    Kimura S, Nakajima Y, Hasegawa S, Tazaki H.
    Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):517-25. PubMed ID: 2664296
    [Abstract] [Full Text] [Related]

  • 2. Effect of oxoplatinum and CBDCA on renal functions in rats.
    Láznícková A, Semecký V, Láznícek M, Zubr V, Koksál J, Kvĕtina J.
    Neoplasma; 1989 Apr; 36(2):161-9. PubMed ID: 2654665
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR.
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K, Akamatsu K, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K.
    Anticancer Res; 1992 Apr; 12(1):49-58. PubMed ID: 1567181
    [Abstract] [Full Text] [Related]

  • 6. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin.
    Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA.
    Exp Mol Pathol; 1989 Oct; 51(2):123-40. PubMed ID: 2680578
    [Abstract] [Full Text] [Related]

  • 7. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
    Kralovánszky J, Prajda N, Kerpel-Fronius S, Gál F, Kiss F.
    Cancer Chemother Pharmacol; 1988 Oct; 21(1):40-4. PubMed ID: 3277733
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ, Sheridan C.
    Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
    Sharma H, Thatcher N, Baer J, Zaki A, Smith A, McAucliffe CA, Crowther D, Owens S, Fox BW.
    Cancer Chemother Pharmacol; 1983 Apr; 11(1):5-7. PubMed ID: 6349844
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
    Horn U, Härtl A, Neuhaus G, Stöckel U, Schröer HP, Hoffmann H.
    Arch Geschwulstforsch; 1989 Apr; 59(4):245-50. PubMed ID: 2802932
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Similar effects of cis-diamminedichloroplatinum(II) and cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) on sodium-coupled glucose uptake in renal brush-border membrane vesicles.
    Potdevin S, Courjault-Gautier F, Ripoche P, Toutain HJ.
    Arch Toxicol; 1998 Oct; 72(10):663-70. PubMed ID: 9851683
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K, Asano K, Nishimura T, Chimata T, Matsuo Y, Tsuchiya M, Ogata H.
    J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.